PTC Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de PTC Therapeutics es Matt Klein , nombrado en Mar 2023, tiene una permanencia de 1.67 años. compensación anual total es $8.94M, compuesta por 8.4% salario y 91.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.068% de las acciones de la empresa, por valor de €2.28M. La antigüedad media del equipo directivo y de la junta directiva es de 5.7 años y 9.4 años, respectivamente.

Información clave

Matt Klein

Chief Executive Officer (CEO)

US$8.9m

Compensación total

Porcentaje del salario del CEO	8.4%
Permanencia del CEO	1.7yrs
Participación del CEO	0.07%
Permanencia media de la dirección	5.7yrs
Promedio de permanencia en la Junta Directiva	9.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Matt Klein en comparación con los beneficios de PTC Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$453m
Jun 30 2024	n/a	n/a	-US$480m
Mar 31 2024	n/a	n/a	-US$579m
Dec 31 2023	US$9m	US$747k	-US$627m
Sep 30 2023	n/a	n/a	-US$642m
Jun 30 2023	n/a	n/a	-US$618m
Mar 31 2023	n/a	n/a	-US$571m
Dec 31 2022	US$5m	US$598k	-US$559m

Compensación vs. Mercado: La compensación total de Matt($USD8.94M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.93M).

Compensación vs. Ingresos: La compensación de Matt ha aumentado mientras la empresa no es rentable.

CEO

Matt Klein (52 yo)

1.7yrs

Permanencia

US$8,937,025

Compensación

Dr. Matthew B. Klein, also known as Matt, M.D., MS, FACS, serves as Chief Executive Officer and Director of PTC Therapeutics, Inc. since March 24, 2023He served as an Independent Director at ClearPoint Neu...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Matthew Klein	CEO & Director	1.7yrs	US$8.94m	0.068% € 2.3m
Stuart Peltz	Co-Founder	26.8yrs	US$5.66m	sin datos
Allan Jacobson	Co-Founder	26.8yrs	US$511.98k	0.016% € 537.2k
Pierre Gravier	Chief Financial Officer	1.3yrs	US$3.01m	0.015% € 519.1k
Mark Boulding	Executive VP & Chief Legal Officer	12.7yrs	US$2.19m	0.063% € 2.1m
Eric Pauwels	Chief Business Officer	9.6yrs	US$2.41m	0.026% € 858.3k
Lee Golden	Executive VP & Chief Medical Officer	4.5yrs	US$2.39m	0.019% € 646.9k
Christine Utter	Senior VP	5.4yrs	US$1.70m	0.022% € 741.9k
Neil Almstead	Chief Technical Operations Officer	5.9yrs	US$2.67m	0.054% € 1.8m
Linda Carter	Senior VP & Chief Information Officer	less than a year	sin datos	sin datos
Alex Kane	Investor Relations Officer	no data	sin datos	sin datos
Jane Baj	Vice President of Corporate Communications	no data	sin datos	sin datos

5.7yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BH3 es experimentado (5.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Matthew Klein	CEO & Director	1.7yrs	US$8.94m	0.068% € 2.3m
Stuart Peltz	Co-Founder	1.7yrs	US$5.66m	sin datos
Allan Jacobson	Co-Founder	26.8yrs	US$511.98k	0.016% € 537.2k
Michael Schmertzler	Independent Chairman of the Board	23.3yrs	US$816.96k	1.95% € 65.3m
David Southwell	Independent Director	18.9yrs	US$438.98k	0.014% € 456.7k
Eric Jacobsen	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Emma Reeve	Independent Director	5.9yrs	US$441.98k	0.0093% € 313.4k
Joseph Puglisi	Member of Scientific Advisory Board	21yrs	sin datos	sin datos
Glenn Steele	Independent Director	9.4yrs	US$426.98k	0.014% € 456.7k
Marvin Wickens	Member of Scientific Advisory Board	no data	sin datos	sin datos
Robert Schneider	Member of Scientific Advisory Board	no data	sin datos	sin datos
Stephanie Okey	Independent Director	5.9yrs	US$421.98k	0.0076% € 255.4k

9.4yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de BH3 se considera experimentada (9.4 años de antigüedad promedio).

PTC Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

PTC Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

CEO & Director recently sold €250k worth of stock

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

CEO, COO & Director recently sold €57k worth of stock

Co-Founder recently sold €110k worth of stock

Co-Founder recently sold €80k worth of stock

Recent updates

PTC Therapeutics, Inc. Announces Topline Results of Cardinals Trial of Utreloxastat in ALS Patients

PTC Therapeutics, Inc. Announces FDA Approval of AADC Deficiency Gene Therapy

New minor risk - Profitability

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: US$1.39 loss per share (vs US$1.76 loss in 3Q 2023)

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2024

PTC Therapeutics Announces FDA Acceptance of Translarna NDA Resubmission

PTC Therapeutics, Inc. Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Maintains Negative Opinion on Translarna Reexamination

PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results

PTC Therapeutics, Inc. Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

New minor risk - Profitability

Second quarter 2024 earnings released: US$1.29 loss per share (vs US$2.66 loss in 2Q 2023)

PTC Therapeutics, Inc. Announces Sepiapterin Nda Submission to Fda

PTC Therapeutics, Inc. Announces Interim PIVOT-HD Results from the Phase 2 PIVOT-HD Study of PTC518 in Huntington's Disease Patients

PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza

PTC Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$1.20 loss per share (vs US$1.89 loss in 1Q 2023)

PTC Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

New major risk - Share price stability

PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

Full year 2023 earnings released: US$8.37 loss per share (vs US$7.79 loss in FY 2022)

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn (ataluren) Following Re-examination Procedure

CEO & Director recently sold €250k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024

PTC Therapeutics, Inc. Provides Updates on Translarna Regulatory Activities

PTC Therapeutics, Inc. Updates Revenue Guidance for Full Year 2023

New major risk - Financial position

PTC Therapeutics, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Financial position

New minor risk - Profitability

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$2.66 loss per share (vs US$2.13 loss in 2Q 2022)

PTC Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

PTC Therapeutics, Inc. Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures

Ptc Therapeutics Shares Positive Interim Data from Pivot-Hd Clinical Trial in Huntington's Disease Patients

PTC Therapeutics, Inc. Announces Strategic Pipeline Prioritization

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

PTC Therapeutics, Inc. Announces Aphenity Trial Achieves Primary Endpoint with Sepiapterin in Adult and Pediatric Patients with Phenylketonuria

First quarter 2023 earnings released: US$1.89 loss per share (vs US$1.78 loss in 1Q 2022)

CEO, COO & Director recently sold €57k worth of stock

Forecast to breakeven in 2025

Full year 2022 earnings released: US$7.79 loss per share (vs US$7.44 loss in FY 2021)

Co-Founder recently sold €110k worth of stock

Co-Founder recently sold €80k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 and 2023

PTC Therapeutics, Inc. Announces Resignation of Dawn Svoronos as Member of the Board of Directors

PTC Therapeutics, Inc. Announces That the Brazilian Health Regulatory Agency, Anvisa (Agência Nacional De Vigilância Sanitária), Has Approved Waylivra™ (Volanesorsen) as the First Treatment for Familial Partial Lipodystrophy (Fpl) in Brazil

Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for PTC Therapeutics, Inc.'s Upstaza™

Insufficient new directors

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.89 loss in 3Q 2021)

PTC Therapeutics, Inc. announced that it expects to receive $499.999989 million in funding from Blackstone Alternative Credit Advisors LP, Blackstone Life Sciences Advisors L.L.C.

PTC Therapeutics, Inc. Provides Update on Ongoing Global PIVOT-HD Trial For PTC518

Insider recently sold €116k worth of stock

PTC Therapeutics, Inc. Provides Key Clinical/Regulatory Updates

Second quarter 2022 earnings released: US$2.13 loss per share (vs US$1.68 loss in 2Q 2021)

PTC Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2022

PTC Therapeutics, Inc. Announces Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency

PTC Therapeutics, Inc. Appoints Alethia Young to its Board of Directors

PTC Therapeutics, Inc. Announces Preliminary Results Presented At ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study

PTC Therapeutics, Inc. Announces FDA Approves Label Extension for Evrysdi for Infants with Spinal Muscular Atrophy Under 2 Months Old

PTC Therapeutics, Inc. Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency

First quarter 2022 earnings released: US$1.78 loss per share (vs US$1.83 loss in 1Q 2021)

PTC Therapeutics, Inc. Provides Earnings Guidance for 2022

Insufficient new directors